Sign in to view content

It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD

David A. Eichenbaum, MD, FASRS

Video
Published 2019

Related

PRN cycles of three monthly anti-VEGF injections in neovascular AMD: 12 and 24 months results.
Touka Banaee, MD
On Demand Cases, Courses, and Papers
2019
Prognostic Value of Subretinal Hyperreflective Material
Russell Pokroy, MD
Updates from the Field
2017
ENVISION Trial 24-Week Data: Phase 2 Study of UBX1325, a New Senolytic Agent for Patients With Wet AMD
Raj K. Maturi, MD
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more